NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

藍伯-伊頓肌無力症候群(LEMS):至2028年的流行病學預測

Lambert-Eaton Myasthenic Syndrome (LEMS) - Epidemiology Forecast-2028

出版商 DelveInsight Business Research LLP 商品編碼 905932
出版日期 按訂單生產 內容資訊 英文 90 Pages
商品交期: 2-10個工作天內
價格
藍伯-伊頓肌無力症候群(LEMS):至2028年的流行病學預測 Lambert-Eaton Myasthenic Syndrome (LEMS) - Epidemiology Forecast-2028
出版日期: 按訂單生產內容資訊: 英文 90 Pages
簡介

本報告提供全球藍伯-伊頓肌無力症候群(LEMS)的相關調查,主要7個國家(美國、德國、法國、義大利、西班牙、英國、日本)的流行病學,患者和疾病概要等資訊。

目錄

第1章 重要的洞察

第2章 報告的介紹

第3章 藍伯-伊頓肌無力症候群:患者概要

  • 患者佔有率(%)2017年的分佈
  • 患者佔有率(%)2028年的分佈

第4章 藍伯-伊頓肌無力症候群:疾病概要

  • 簡介
  • 徵兆及症狀
  • 原因
  • 危險因素
  • 病理生理學
  • 病因
  • 臨床症狀
  • 診斷
    • 診斷演算法

第5章 流行病學及患者人口

  • 主要調查結果
  • 主要7個國家的總流行案例
  • 在主要7個國家中被診斷的一般病例
  • 在主要7個國家中性別確診的一般病例
  • 在主要7個國家中各類型確診的一般病例

第6章 美國流行病學

第7章 流行病學歐洲5個國家

  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國

第8章 日本流行病學

第9章 附錄

  • 報告方法

第10章 DelveInsight的服務內容

第11章 免責聲明

目錄
Product Code: DIEI0373

DelveInsight's 'Lambert-Eaton Myasthenic Syndrome (LEMS) - Epidemiology Forecast-2028' report deliver an in-depth understanding of the disease, historical & forecasted epidemiology of LEMS in the United States, EU5 (Germany, Spain, Italy, France and the United Kingdom), and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2028

Lambert-Eaton Myasthenic Syndrome (LEMS) - Disease Understanding

The DelveInsight Lambert-Eaton Myasthenic Syndrome (LEMS) epidemiology report gives a thorough understanding of the Lambert-Eaton Myasthenic Syndrome (LEMS) by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends.

Lambert-Eaton Myasthenic Syndrome (LEMS)

According to the Muscular Dystrophy Association, Lambert-Eaton myasthenic syndrome (LEMS) is an autoimmune disease in which the immune system attacks the body's own tissues. The attack occurs at the connection between nerve and muscle (the neuromuscular junction) and interferes with the ability of nerve cells to send signals to muscle cells. Specifically, the immune system attacks the calcium channels on nerve endings that are required to trigger the release of chemicals (acetylcholine). With fewer calcium channels, the nerve ending releases less acetylcholine. Acetylcholine is a chemical messenger that triggers muscle contraction. In people with LEMS, the lowered levels of acetylcholine are not sufficient to cause normal muscle contractions, causing muscle weakness. The disease is named for Edward Lambert and Lee Eaton, neurologists at the Mayo Clinic in Rochester, Minn., who first described the myasthenic syndrome in the 1950s and 1960s.

The Lambert-Eaton Myasthenic Syndrome (LEMS) epidemiology division provide insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Prevalence of Lambert-Eaton Myasthenic Syndrome (LEMS) in 7MM, Total Diagnosed Prevalence of LEMS in 7MM, Gender-specific Diagnosed Prevalence of LEMS, Type-specific Diagnosed Prevalence of LEMS, and Diagnosed Prevalence of LEMS by malignancy) scenario of Lambert-Eaton Myasthenic Syndrome (LEMS) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.

According to DelveInsight, the total number of diagnosed prevalent population of Lambert-Eaton Myasthenic Syndrome (LEMS) was found to be 3,349, in 7MM in the year 2017.

Based on the etiology, Lambert Eaton Myasthenic Syndrome (LEMS) is divided into two types; Paraneoplastic and Idiopathic. There were total 1,978 diagnosed prevalent cases of LEMS in the United States in 2017, out of which 1,154 accounted for Paraneoplastic and 824 cases accounted for Idiopathic. These cases are expected to increase and reach up to 1,441 and 1,029 cases respectively, by 2028.

As per DelveInsight assessments, in the 7MM, the majority of cases of Lambert Eaton Myasthenic Syndrome (LEMS) are Paraneoplastic form as compared to Idiopathic form. Among the two forms of Lambert-Eaton myasthenic syndrome i.e. paraneoplastic and idiopathic, the paraneoplastic form, constitutes more than a half of the cases and is mostly associated with intrathoracic neoplasms. Most of the cases in patients were seen with Small Cell Lung Cancer (SCLC); other subtypes of lung cancer are extremely rare.

Among the EU-5 countries, Germany witnessed the highest prevalent population accounting for 6.93% of the total prevalent cases in 7MM, followed by France and the United Kingdom. On the other hand, Spain witnessed the lowest number of prevalent cases in 2017.

Report Scope

  • The report covers a descriptive overview of the Lambert Eaton Myasthenic Syndrome (LEMS), explaining its causes, risk factors, pathophysiology and currently available therapies.
  • Comprehensive insight has been provided into the epidemiology of Lambert Eaton Myasthenic Syndrome (LEMS) in the 7MM countries covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • Assesses growth opportunities in the 7MM countries with respect to the patient population.

Key strengths

  • 10 Year Forecast
  • 7MM countries
  • Total Patient Pool with Lambert Eaton Myasthenic Syndrome (LEMS) by types

Key assessments

  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by types

Table of Contents

1. Key Insights

2. Report Introduction

3. Lambert-Eaton Myasthenic Syndrome (LEMS): Patient Overview at a Glance

  • 3.1. Patient Share (%) Distribution of LEMS in 2017
  • 3.2. Patient Share (%) Distribution of LEMS in 2028

4. Lambert-Eaton Myasthenic Syndrome (LEMS): Disease Overview

  • 4.1. Introduction
  • 4.2. Signs and Symptoms
  • 4.3. Cause of Lambert-Eaton Myasthenic Syndrome
  • 4.4. Risk Factors
  • 4.5. Pathophysiology Lambert-Eaton Myasthenic Syndrome
  • 4.6. Pathogenesis
  • 4.7. Clinical Manifestations
  • 4.8. Diagnosis
    • 4.8.1. Diagnostic Algorithm

5. Epidemiology and Patient Population

  • 5.1. Key Findings
  • 5.2. Total Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in 7MM
  • 5.3. Total Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in 7MM
  • 5.4. Gender-Specific Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in 7MM
  • 5.5. Type-Specific Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in 7MM

6. United States Epidemiology

  • 6.1. Assumptions and Rationale
  • 6.2. Total Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in the United States
  • 6.3. Total Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in the United States
  • 6.4. Gender-Specific Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in the United States
  • 6.5. Type Specific Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in the United States
  • 6.6. Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) by Malignancy in the United States

7. EU-5 Epidemiology

  • 7.1. Germany
    • 7.1.1. Total Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Germany
    • 7.1.2. Total Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Germany
    • 7.1.3. Gender-Specific Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Germany
    • 7.1.4. Type Specific Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Germany
    • 7.1.5. Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) by Malignancy in Germany
  • 7.2. France
    • 7.2.1. Total Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in France
    • 7.2.2. Total Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in France
    • 7.2.3. Gender-Specific Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in France
    • 7.2.4. Type Specific Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in France
    • 7.2.5. Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) by Malignancy in France
  • 7.3. Italy
    • 7.3.1. Total Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Italy
    • 7.3.2. Total Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Italy
    • 7.3.3. Gender-Specific Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Italy
    • 7.3.4. Type Specific Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Italy
    • 7.3.5. Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) by Malignancy in Italy
  • 7.4. Spain
    • 7.4.1. Total Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Spain
    • 7.4.2. Total Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Spain
    • 7.4.3. Gender-Specific Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Spain
    • 7.4.4. Type Specific Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Spain
    • 7.4.5. Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) by Malignancy in Spain
  • 7.5. United Kingdom
    • 7.5.1. Total Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in the United Kingdom
    • 7.5.2. Total Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in the United Kingdom
    • 7.5.3. Gender Specific Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in the United Kingdom
    • 7.5.4. Type Specific Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in the United Kingdom
    • 7.5.5. Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) by Malignancy in the United Kingdom

8. Japan Epidemiology

  • 8.1. Assumptions and Rationale
  • 8.2. Total Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Japan
  • 8.3. Total Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Japan
  • 8.4. Gender Specific Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Japan
  • 8.5. Type Specific Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Japan
  • 8.6. Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) by Malignancy in Japan

9. Appendix

  • 9.1. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

List of Tables

  • Table 1 Signs and Symptoms of LEMS
  • Table 2 Classification and characteristics of voltage-gated calcium channels (VGCC)
  • Table 3 Total Prevalent Cases of LEMS in 7MM (2017-2028)
  • Table 4 Total Diagnosed Prevalent Cases of LEMS in 7MM (2017-2028)
  • Table 5 Gender-Specific Diagnosed Prevalent Cases of LEMS in 7MM (2017-2028)
  • Table 6 Type-Specific Diagnosed Prevalent Cases of LEMS in 7MM (2017-2028)
  • Table 7 Total Prevalent Cases of LEMS in the United States (2017-2028)
  • Table 8 Total Diagnosed Prevalent Cases of LEMS in the United States (2017-2028)
  • Table 9 Gender Specific Diagnosed Prevalent Cases of LEMS in the United States (2017-2028)
  • Table 10 Type Specific Diagnosed Prevalent Cases of LEMS in the United States (2017-2028)
  • Table 11 Diagnosed Prevalent Cases of LEMS by Malignancy in the United States (2017-2028)
  • Table 12 Total Prevalent Cases of LEMS in Germany (2017-2028)
  • Table 13 Total Diagnosed Prevalent Cases of LEMS in Germany (2017-2028)
  • Table 14 Gender Specific Diagnosed Prevalent Cases of LEMS in Germany (2017-2028)
  • Table 15 Type Specific Diagnosed Prevalent Cases of LEMS in Germany (2017-2028)
  • Table 16 Diagnosed Prevalent Cases of LEMS by Malignancy in Germany (2017-2028)
  • Table 17 Total Prevalent Cases of LEMS in France (2017-2028)
  • Table 18 Total Diagnosed Prevalent Cases of LEMS in France (2017-2028)
  • Table 19 Gender Specific Diagnosed Prevalent Cases of LEMS in France (2017-2028)
  • Table 20 Type Specific Diagnosed Prevalent Cases of LEMS in France (2017-2028)
  • Table 21 Diagnosed Prevalent Cases of LEMS by Malignancy in France (2017-2028)
  • Table 22 Total Prevalent Cases of LEMS in Italy (2017-2028)
  • Table 23 Total Diagnosed Prevalent Cases of LEMS in Italy (2017-2028)
  • Table 24 Gender Specific Diagnosed Prevalent Cases of LEMS in Italy (2017-2028)
  • Table 25 Type Specific Diagnosed Prevalent Cases of LEMS in Italy (2017-2028)
  • Table 26 Diagnosed Prevalent Cases of LEMS by Malignancy in Italy (2017-2028)
  • Table 27 Total Prevalent Cases of LEMS in Spain (2017-2028)
  • Table 28 Total Diagnosed Prevalent Cases of LEMS in Spain (2017-2028)
  • Table 29 Gender Specific Diagnosed Prevalent Cases of LEMS in Spain (2017-2028)
  • Table 30 Type Specific Diagnosed Prevalent Cases of LEMS in Spain (2017-2028)
  • Table 31 Diagnosed Prevalent Cases of LEMS by Malignancy in Spain (2017-2028)
  • Table 32 Total Prevalent Cases of LEMS in the United Kingdom (2017-2028)
  • Table 33 Total Diagnosed Prevalent Cases of LEMS in the United Kingdom (2017-2028)
  • Table 34 Gender Specific Diagnosed Prevalent Cases of LEMS in the United Kingdom (2017-2028)
  • Table 35 Type Specific Diagnosed Prevalent Cases of LEMS in the United Kingdom (2017-2028)
  • Table 36 Diagnosed Prevalent Cases of LEMS by Malignancy in the United Kingdom (2017-2028)
  • Table 37 Total Prevalent Cases of LEMS in Japan (2017-2028)
  • Table 38 Total Diagnosed Prevalent Cases of LEMS in Japan (2017-2028)
  • Table 39 Gender Specific Diagnosed Prevalent Cases of LEMS in Japan (2017-2028)
  • Table 40 Type Specific Diagnosed Prevalent Cases of LEMS in Japan (2017-2028)
  • Table 41 Diagnosed Prevalent Cases of LEMS by Malignancy in Japan (2017-2028)

List of Figures

  • Figure 1 Signs and Symptoms of LEMS
  • Figure 2 Lambert and colleague's classical description of the clinical features
  • Figure 3 Mechanism of Action
  • Figure 4 Pathophysiology of LEMS and effects of symptomatic treatment
  • Figure 5 Diagnostic Algorithm
  • Figure 6 LEMS diagnosis and oncological screening algorithm
  • Figure 7 Diagnostic Algorithm of LEMS
  • Figure 8 Diagnostic algorithm for clinically suspected LEMS
  • Figure 9 Total Prevalent Cases of LEMS in 7MM (2017-2028)
  • Figure 10 Total Diagnosed Prevalent Cases of LEMS in 7MM (2017-2028)
  • Figure 11 Gender-Specific Diagnosed Prevalent Cases of LEMS in 7MM (2017-2028)
  • Figure 12 Type-Specific Diagnosed Prevalent Cases of LEMS in 7MM (2017-2028)
  • Figure 13 Total Prevalent Cases of LEMS in the United States (2017-2028)
  • Figure 14 Total Diagnosed Prevalent Cases of LEMS in the United States (2017-2028)
  • Figure 15 Gender Specific Diagnosed Prevalent Cases of LEMS in the United States (2017-2028)
  • Figure 16 Type Specific Diagnosed Prevalent Cases of LEMS in the United States (2017-2028)
  • Figure 17 Diagnosed Prevalent Cases of LEMS by Malignancy in the United States (2017-2028)
  • Figure 18 Total Prevalent Cases of LEMS in Germany (2017-2028)
  • Figure 19 Total Diagnosed Prevalent Cases of LEMS in Germany (2017-2028)
  • Figure 20 Gender Specific Diagnosed Prevalent Cases of LEMS in Germany (2017-2028)
  • Figure 21 Type Specific Diagnosed Prevalent Cases of LEMS in Germany (2017-2028)
  • Figure 22 Diagnosed Prevalent Cases of LEMS by Malignancy in Germany (2017-2028)
  • Figure 23 Total Prevalent Cases of LEMS in France (2017-2028)
  • Figure 24 Total Diagnosed Prevalent Cases of LEMS in France (2017-2028)
  • Figure 25 Gender Specific Diagnosed Prevalent Cases of LEMS in France (2017-2028)
  • Figure 26 Type Specific Diagnosed Prevalent Cases of LEMS in France (2017-2028)
  • Figure 27 Diagnosed Prevalent Cases of LEMS by Malignancy in France (2017-2028)
  • Figure 28 Total Prevalent Cases of LEMS in Italy (2017-2028)
  • Figure 29 Total Diagnosed Prevalent Cases of LEMS in Italy (2017-2028)
  • Figure 30 Gender Specific Diagnosed Prevalent Cases of LEMS in Italy (2017-2028)
  • Figure 31 Type Specific Diagnosed Prevalent Cases of LEMS in Italy (2017-2028)
  • Figure 32 Diagnosed Prevalent Cases of LEMS by Malignancy in Italy (2017-2028)
  • Figure 33 Total Prevalent Cases of LEMS in Spain (2017-2028)
  • Figure 34 Total Diagnosed Prevalent Cases of LEMS in Spain (2017-2028)
  • Figure 35 Gender Specific Diagnosed Prevalent Cases of LEMS in Spain (2017-2028)
  • Figure 36 Type Specific Diagnosed Prevalent Cases of LEMS in Spain (2017-2028)
  • Figure 37 Diagnosed Prevalent Cases of LEMS by Malignancy in Spain (2017-2028)
  • Figure 38 Total Prevalent Cases of LEMS in the United Kingdom (2017-2028)
  • Figure 39 Total Diagnosed Prevalent Cases of LEMS in the United Kingdom (2017-2028)
  • Figure 40 Gender Specific Diagnosed Prevalent Cases of LEMS in the United Kingdom (2017-2028)
  • Figure 41 Type Specific Diagnosed Prevalent Cases of LEMS in the United Kingdom (2017-2028)
  • Figure 42 Diagnosed Prevalent Cases of LEMS by Malignancy in the United Kingdom (2017-2028)
  • Figure 43 Total Prevalent Cases of LEMS in Japan (2017-2028)
  • Figure 44 Total Diagnosed Prevalent Cases of LEMS in Japan (2017-2028)
  • Figure 45 Gender Specific Diagnosed Prevalent Cases of LEMS in Japan (2017-2028)
  • Figure 46 Type Specific Diagnosed Prevalent Cases of LEMS in Japan (2017-2028)
  • Figure 47 Diagnosed Prevalent Cases of LEMS by Malignancy in Japan (2017-2028)